- Home
- Software Solutions
- Resources
- Corporate
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
Sponsors:
| Phases:
| |
| Indications | Acronym: | |
| ||
Age Groups:
| Gender: Both | |
Names:
| Enrollment: 37 | |
Additional information about NCT01009203.